Date/time: Tuesday, August 18, 2026 from 1:00 – 2:30 PM ET
Description: This CME symposium equips clinicians to deliver lifelong, patient-centered care for individuals with congenital adrenal hyperplasia (CAH). Faculty will review the mechanisms, efficacy, safety, and tolerability of current and emerging therapeutic options, highlighting advances that may reshape glucocorticoid management. The session will emphasize shared decision-making strategies tailored to developmental stages, including best practices for transitioning pediatric patients to adult care. Participants will also learn to design comprehensive, evidence-based care plans that address the long‑term metabolic, cardiovascular, reproductive, and psychosocial sequelae of chronic glucocorticoid exposure—even after dose normalization—to optimize outcomes across the lifespan.
Learning Objectives:
Evaluate the mechanisms, efficacy, safety, and tolerability profiles of current and emerging agents for CAH
Integrate SDM approaches for patient management across the lifespan, including the transition of pediatric patients to adult care
Develop comprehensive, evidence-based care plans to address the long-term sequalae arising from chronic glucocorticoid exposure in CAH, even after dose normalization
CMEs:
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
Sponsored by the Med Learning Group